Condition

Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 18 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials18

Recruiting3

Common interventions25

Lead sponsors shown15

Clinical trials

18 shown

Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung CancerNCT06523673 · 2024-09-01

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerNCT06343402 · 2024-05-22

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02

A Study of DS-3939a in Participants With Solid TumorsNCT07739966 · 2026-10-01

NOT_YET_RECRUITING

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550 · 2023-06-01

ACTIVE_NOT_RECRUITING

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsNCT05364073 · 2022-06-30

ACTIVE_NOT_RECRUITING

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)NCT05226598 · 2022-03-24

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With CapmatinibNCT05675683 · 2021-10-01

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)NCT04863248 · 2021-04-30

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLCNCT05223595 · 2021-04-02

Plasma-Adapted First-Line Pembro In NSCLCNCT04166487 · 2020-01-13

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)NCT03976375 · 2019-06-26

A Study of ADXS-NEO Expressing Personalized Tumor AntigensNCT03265080 · 2018-03-28

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)NCT02411448 · 2015-05-06

ACTIVE_NOT_RECRUITING

Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid TumorsNCT01936961 · 2013-06-01

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT01395758 · 2011-07-01

A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain MetastasesNCT00872482 · 2009-04-01

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerNCT04599712

APPROVED_FOR_MARKETING

Common interventions

Leading sponsors

ArriVent BioPharma, Inc. 2 Merck Sharp & Dohme LLC 2 Advaxis, Inc. 1 ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 1 Changchun GeneScience Pharmaceutical Co., Ltd. 1 Daiichi Sankyo 1 Eli Lilly and Company 1 G1 Therapeutics, Inc. 1 Janssen Research & Development, LLC 1 Julia K. Rotow, MD 1 Mirati Therapeutics Inc. 1 Novartis Pharmaceuticals 1 Second Affiliated Hospital, Zhejiang University, School of Medicine 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 1 Western Regional Medical Center 1

Trial status mix

ACTIVE_NOT_RECRUITING4

TERMINATED4

COMPLETED3

RECRUITING3

APPROVED_FOR_MARKETING1

NOT_YET_RECRUITING1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE26

PHASE36

PHASE15

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.